{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:19:49Z","timestamp":1793254789009,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100022110","name":"bioM\u00e9rieux","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Septic arthritis is a serious condition with significant morbidity and mortality, routinely diagnosed using culture. The FDA has recently approved the rapid molecular BioFire\u00ae\u00a0Joint Infection Panel (BJIP) for synovial fluid. We aimed to evaluate the BJIP compared to culture and its potential use in patient management. A multicentre retrospective evaluation of BJIP was conducted in the UK and Ireland. Positive percent agreement (PPA) and negative percent agreement (NPA) were calculated between the BJIP and routine culture. A multidisciplinary team (MDT) discussion addressing the optimal or potential case use of the assay practice was facilitated. Three hundred ninety-nine surplus synovial fluid samples (~\u200970% from native joints) from eight centres were processed using BJIP in addition to routine culture. An increased yield of positive results was detected using BJIP compared to routine culture (98 vs 83), giving an overall PPA of 91.6% and overall NPA of 93% for the BJIP compared to culture results. The BJIP detected resistant markers and additional organisms that could influence antibiotic choices including <jats:italic>Neisseria gonorrhoeae<\/jats:italic> and <jats:italic>Kingella kingae<\/jats:italic>. The MDT agreed that the assay could be used, in addition to standard methods, in adult and children patients with specialist advice use based on local needs. Rapid results from BJIP were assessed as having potential clinical impact on patient management. Organisms not included in the panel may be clinically significant and may limit the value of this test for PJI.<\/jats:p>","DOI":"10.1007\/s10096-022-04538-w","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:03:27Z","timestamp":1670371407000},"page":"169-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["A multicentre evaluation and expert recommendations of use of the newly developed BioFire Joint Infection polymerase chain reaction panel"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-0302","authenticated-orcid":false,"given":"Kordo","family":"Saeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusreen","family":"Ahmad-Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Annett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Boran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwennan","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Leach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Nayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Milburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanine","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Moffat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke S. P.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaan Ashk","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionnuala","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Peach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Petridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Reidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathyruban","family":"Selvaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Wearmouth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Aldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"issue":"9717","key":"4538_CR1","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/S0140-6736(09)61595-6","volume":"375","author":"CJ Mathews","year":"2010","unstructured":"Mathews CJ, Weston VC, Jones A, Field M, Coakley G (2010) Bacterial septic arthritis in adults. Lancet 375(9717):846\u2013855. https:\/\/doi.org\/10.1016\/S0140-6736(09)61595-6","journal-title":"Lancet"},{"issue":"11","key":"4538_CR2","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s10067-008-0934-9","volume":"27","author":"AS Al Arfaj","year":"2008","unstructured":"Al Arfaj AS (2008) A prospective study of the incidence and characteristics of septic arthritis in a teaching hospital in Riyadh, Saudi Arabia. Clin Rheumatol 27(11):1403\u20131410. https:\/\/doi.org\/10.1007\/s10067-008-0934-9","journal-title":"Clin Rheumatol"},{"key":"4538_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12879-016-1540-0","volume":"16","author":"J Ferrand","year":"2016","unstructured":"Ferrand J, El Samad Y, Brunschweiler B, Grados F, Dehamchia-Rehailia N, S\u00e9journe A, Schmit JL, Gabrion A, Fardellone P, Paccou J (2016) Morbimortality in adult patients with septic arthritis: a three-year hospital-based study. BMC Infect Dis 16:239. https:\/\/doi.org\/10.1186\/s12879-016-1540-0","journal-title":"BMC Infect Dis"},{"issue":"12","key":"4538_CR4","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1093\/rheumatology\/kew323","volume":"55","author":"AI Rutherford","year":"2016","unstructured":"Rutherford AI, Subesinghe S, Bharucha T, Ibrahim F, Kleymann A, Galloway JB (2016) A population study of the reported incidence of native joint septic arthritis in the United Kingdom between 1998 and 2013. Rheumatology (Oxford, England) 55(12):2176\u20132180. https:\/\/doi.org\/10.1093\/rheumatology\/kew323","journal-title":"Rheumatology (Oxford, England)"},{"issue":"13","key":"4538_CR5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.297.13.1478","volume":"297","author":"ME Margaretten","year":"2007","unstructured":"Margaretten ME, Kohlwes J, Moore D, Bent S (2007) Does this adult patient have septic arthritis? JAMA 297(13):1478\u20131488. https:\/\/doi.org\/10.1001\/jama.297.13.1478","journal-title":"JAMA"},{"issue":"Suppl 1","key":"4538_CR6","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1093\/jac\/dku248","volume":"69","author":"K Saeed","year":"2014","unstructured":"Saeed K (2014) Diagnostics in prosthetic joint infections. J Antimicrob Chemother 69(Suppl 1):i11\u2013i19. https:\/\/doi.org\/10.1093\/jac\/dku248","journal-title":"J Antimicrob Chemother"},{"key":"4538_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/BCO.0b013e3181f20439","volume":"21","author":"K Saeed","year":"2010","unstructured":"Saeed K, Ahmad N, Pallett A, Guiver M, Marsh P (2010) Specific staphylococcal polymerase chain reaction can be a complementary tool for identifying causative organisms and guiding antibiotic management in orthopaedic infections. Curr Ortho Pract 21:628\u2013631","journal-title":"Curr Ortho Pract"},{"issue":"7","key":"4538_CR8","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1586\/14737159.2015.1046437","volume":"15","author":"K Saeed","year":"2015","unstructured":"Saeed K, Ahmad-Saeed N (2015) The impact of PCR in the management of prosthetic joint infections. Expert Rev Mol Diagn 15(7):957\u2013964. https:\/\/doi.org\/10.1586\/14737159.2015.1046437","journal-title":"Expert Rev Mol Diagn"},{"key":"4538_CR9","doi-asserted-by":"publisher","first-page":"7965","DOI":"10.1038\/s41598-020-64739-1","volume":"10","author":"D Aggarwal","year":"2020","unstructured":"Aggarwal D, Kanitkar T, Narouz M et al (2020) Clinical utility and cost-effectiveness of bacterial 16S rRNA and targeted PCR based diagnostic testing in a UK microbiology laboratory network. Sci Rep 10:7965. https:\/\/doi.org\/10.1038\/s41598-020-64739-1","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"4538_CR10","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1093\/ofid\/ofaa439.518","volume":"7","author":"C Graue","year":"2020","unstructured":"Graue C, Schmitt BH, Waggoner A, Laurent F, Abad L, Bauer T, Mazariegos I, Balada-Llasat JM, Horn J, Wolk D, Jefferis A, Hermans M, Verhoofstad I, Butler-Wu S, Butler-Wu S, Umali-Wilcox M, Murphy CN, Cabrera BJ, Esteban J, Macias-Valcayo A, Jay C (2020) 322. Evaluation of the BioFire\u00ae Bone and Joint Infection (BJI) panel for the detection of microorganisms and antimicrobial resistance genes in synovial fluid specimens. Open Forum Infect Dis 7(Suppl 1):S233\u2013S234. https:\/\/doi.org\/10.1093\/ofid\/ofaa439.518","journal-title":"Open Forum Infect Dis"},{"key":"4538_CR11","unstructured":"U.K. Health Security Agency (2022) UK standards for microbiological investigations (SMI) B 26: investigation of fluids from normally sterile sites. https:\/\/www.gov.uk\/government\/publications\/smi-b-26-investigation-of-fluids-from-normally-sterile-sites (accessed 10th April 2022)"},{"key":"4538_CR12","unstructured":"U.K. Health Security Agency (2022) UK standards for microbiological investigations (SMI) B 44: investigation of orthopaedic implant associated infections. https:\/\/www.gov.uk\/government\/publications\/smi-b-44-investigation-of-prosthetic-joint-infection-samples (accessed 10th April 2022)"},{"key":"4538_CR13","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1002\/art.1780381215.]","volume":"38","author":"CJE Kaandorp","year":"1995","unstructured":"Kaandorp CJE, Schaardenburg D, Krijnen P, Habbema JDF, Laae MAFJ (1995) Risk factors for septic arthritis in patients with joint disease A prospective study. Arthritis Rheum 38:1819\u20131825. https:\/\/doi.org\/10.1002\/art.1780381215.]","journal-title":"Arthritis Rheum"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-022-04538-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-022-04538-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-022-04538-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T12:34:52Z","timestamp":1673526892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-022-04538-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["4538"],"URL":"https:\/\/doi.org\/10.1007\/s10096-022-04538-w","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,7]]},"assertion":[{"value":"27 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All sites obtained individual approval via their research ethics and\/or governance boards and recorded the study a service evaluation project or registered it as a quality improvement project. All data was collected and stored in accordance with the Data Protection Act and the General Data Protection Regulation (GDPR) and anonymised prior to sharing with the wider joint infection study team.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not sought as service evaluation and anonymised data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not sought as service evaluation and anonymised data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KS has received research grants and speaker fees from Pfizer, Thermo Fisher, and Menarini. LSPM has consulted for and received speaker fees from bioMerieux, Pfizer, Eumedica, Shionogi, Pulmocide, Umovis Labs, DNA Electronics, Kent Pharma, and Sumitovant and received research grants from the UK National Institute for Health Research (NIHR), LifeArc, and the CW\u2009+\u2009charity. SEB held research funding through an MRC RCUK\/UKRI Innovation Fellowship (MR\/R016895\/1) and the North West MRC Scheme in Clinical Pharmacology (MR\/N025989\/1). She received research support from Roche Pharma and has consulted for\/received speaker fees from Sumitovant and Shionogi. CA received speaker fees from bioMerieux.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}